Literature DB >> 2864402

Ventricular somatostatin-like immunoreactivity in patients with basal ganglia disease.

H Cramer, A Wolf, K Rissler, K Weigel, C Ostertag.   

Abstract

The concentrations of somatostatin-like immunoreactivity (SLI) in lateral ventricular fluid of patients with extrapyramidal motor disease were determined by specific radio-immunoassay. Mean SLI levels were significantly lower in patients with Parkinson's disease (mean +/- SEM); 42.9 +/- 2.9 fmol/ml) and in patients with dystonic syndromes (39.4 +/- 3.2) than in patients with benign essential tremor (65.3 +/- 9.7). The lowest levels were found in patients with athetosis (34.7 +/- 5.4). In parkinsonian patients somatostatin levels correlated with the degree of akinesia, rigidity and autonomic disturbances.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2864402     DOI: 10.1007/bf00313783

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  28 in total

1.  Radioimmunoassay for GH-release inhibiting hormone.

Authors:  A Arimura; H Sato; D H Coy; A V Schally
Journal:  Proc Soc Exp Biol Med       Date:  1975-03

2.  Opiate-receptor mediated changes in monoamine synthesis in rat brain.

Authors:  J A Garcia-Sevilla; L Ahtee; T Magnusson; A Carlsson
Journal:  J Pharm Pharmacol       Date:  1978-10       Impact factor: 3.765

3.  Huntington's chorea-- measurements of somatostatin, substance P and cyclic nucleotides in the cerebrospinal fluid.

Authors:  H Cramer; J Kohler; G Oepen; G Schomburg; E Schröter
Journal:  J Neurol       Date:  1981       Impact factor: 4.849

4.  Ultrastructural features of immunoreactive somatostatin neurons in the rat caudate nucleus.

Authors:  M DiFiglia; N Aronin
Journal:  J Neurosci       Date:  1982-09       Impact factor: 6.167

5.  The immunocytochemical localization of somatostatin-containing neurons in the rat central nervous system.

Authors:  J C Finley; J L Maderdrut; L J Roger; P Petrusz
Journal:  Neuroscience       Date:  1981       Impact factor: 3.590

6.  Depressant action of TRH, LH-RH and somatostatin on activity of central neurones.

Authors:  L P Renaud; J B Martin; P Brazeau
Journal:  Nature       Date:  1975-05-15       Impact factor: 49.962

7.  Analysis of neurotransmitter metabolites and adenosine 3',5'-monophosphate in the CSF of patients with extrapyramidal motor disorders.

Authors:  H Cramer; J M Warter; B Renaud
Journal:  Adv Neurol       Date:  1984

8.  Parkinson's disease and benign essential tremor: somatostatin-like immunoreactivity in the cerebrospinal fluid.

Authors:  S E Christensen; E Dupont; K Mondrup; B F Olivarius; H Orskov
Journal:  Adv Neurol       Date:  1984

9.  Dopamine and norepinephrine stimulate somatostatin release by median eminence fragments in vitro.

Authors:  A Negro-Vilar; S R Ojeda; A Arimura; S M McCann
Journal:  Life Sci       Date:  1978-10-09       Impact factor: 5.037

10.  Effects of somatostatin on dopamine sensitive adenylate cyclase activity in the caudate-putamen of the rat.

Authors:  A Moser; C Reavill; P Jenner; C D Marsden; H Cramer
Journal:  Exp Brain Res       Date:  1986       Impact factor: 1.972

View more
  3 in total

1.  Somatostatin-like immunoreactivity and substance-P-like immunoreactivity in the CSF of patients with senile dementia of Alzheimer type, multi-infarct syndrome and communicating hydrocephalus.

Authors:  H Cramer; D Schaudt; K Rissler; D Strubel; J M Warter; F Kuntzmann
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

2.  Substance P-like immunoreactivity and somatostatin-like immunoreactivity in the ventricular fluid of patients with chronic pain syndromes.

Authors:  S Jost; C Reuner; J Geiger; M Mohadjer; E Milios; H Cramer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1991       Impact factor: 5.270

Review 3.  Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Authors:  Félix J Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Front Cell Neurosci       Date:  2014-11-11       Impact factor: 5.505

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.